Skip to content
OpenCapital
Get started

Bausch + Lomb BLCO Pharmaceuticals — Total revenues

Other segment segments

Vision Care
$711M+8.4%
Surgical
$228M+6.5%

Similar metrics at other companies

Kiniksa Pharmaceuticals International, plc logo
KNSAPharmaceutical — Revenue
$214.27M+55.5%
HWK
HWKNPharmaceutical — Revenue
$8.32M+15.1%
Vertex Pharmaceuticals logo
VRTXPharmaceuticals — Product revenues, net
$2.99B+7.8%
Baxter International logo
BAXPharmaceuticals — Net Sales
$621M+6.9%
Gilead Sciences logo
GILDProduct sales — Total revenues
$6.95B+5.0%
Rhythm Pharmaceuticals, Inc. logo
RYTMSingle reportable segment — Total revenues
$60.11M+83.8%

Other financials

Income statement

See full
Revenue$1.2B+9.4%
Operating income$33.0M+140%
Net income-$71.0M+66.5%
EPS (diluted)-$0.20+66.7%

Balance sheet

See full
Cash & equivalents$279.0M+29.8%
Total debt$5.0B+4.3%
Total equity$6.4B+0.3%
Total assets$13.8B+2.6%

Cash flow

See full
Operating cash flow$32.0M+228%
CapEx$100.0M-9.1%
Free cash flow-$68.0M+49.6%

Valuation

See full
Market cap$5.3B+10.2%

Profitability

See full
Operating margin4.4%+2.9pp
Net margin-4.2%-1.3pp
FCF margin-3.4%0.0pp

Returns & leverage

See full
Return on equity-3.4%-0.9pp
Debt / equity0.8×0.0×
Current ratio1.5×0.0×

Where this comes from

Reported directly by Bausch + Lomb in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Bausch + Lomb’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bausch + Lomb's pharmaceuticals — total revenues.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bausch + Lomb's pharmaceuticals — total revenues?
Bausch + Lomb (BLCO) reported pharmaceuticals — total revenues of $266M in Q1 2026.
How has Bausch + Lomb's pharmaceuticals — total revenues changed year-over-year?
Bausch + Lomb's pharmaceuticals — total revenues increased by 19.8% year-over-year, from $222M to $266M.
What is the long-term trend for Bausch + Lomb's pharmaceuticals — total revenues?
Over 4 years (2021 to 2025), Bausch + Lomb's pharmaceuticals — total revenues has grown at a 21.7% compound annual growth rate (CAGR), from $493M to $1.08B.
What does pharmaceuticals — total revenues mean?
Represents the total gross inflow of economic benefits generated from the sale of ophthalmic pharmaceutical products and related services. This is a primary indicator of the segment's market demand, pricing power, and overall commercial success in the vision care industry.